BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37755617)

  • 1. USP10 promotes intrahepatic cholangiocarcinoma cell survival and stemness via SNAI1 deubiquitination.
    Zhu W; Ye B; Yang S; Li Y
    J Mol Histol; 2023 Dec; 54(6):703-714. PubMed ID: 37755617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
    Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
    J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
    Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
    J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
    Jin J; Ryu HS; Lee KB; Jang JJ
    PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
    Li J; Tian F; Li D; Chen J; Jiang P; Zheng S; Li X; Wang S
    FEBS Lett; 2014 Sep; 588(18):3491-500. PubMed ID: 25131931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aquaporin 1 is a prognostic marker and inhibits tumour progression through downregulation of Snail expression in intrahepatic cholangiocarcinoma.
    Zhuang MQ; Jiang XL; Liu WD; Xie QH; Wang P; Dong LW; Hu HP; Zhou HB; Zhou YB
    Dig Liver Dis; 2023 Aug; 55(8):1133-1140. PubMed ID: 36642562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.
    Zhang MX; Gan W; Jing CY; Zheng SS; Yi Y; Zhang J; Xu X; Lin JJ; Zhang BH; Qiu SJ
    Mol Carcinog; 2019 Jan; 58(1):19-30. PubMed ID: 30182496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
    Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
    Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
    Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
    Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
    Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
    Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
    Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
    Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma.
    Xiong X; Sun D; Chai H; Shan W; Yu Y; Pu L; Cheng F
    Biochem Biophys Res Commun; 2015 Sep; 465(2):262-9. PubMed ID: 26255969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
    Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.
    Zhu H; Mi Y; Jiang X; Zhou X; Li R; Wei Z; Jiang H; Lu J; Sun X
    J Cancer Res Clin Oncol; 2016 May; 142(5):969-80. PubMed ID: 26825606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway.
    Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L
    Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma.
    Zhao Z; Ma J; Wu K; Chen L; Yu J; Hu W; Zhang K
    Clin Transl Oncol; 2016 Sep; 18(9):878-83. PubMed ID: 26563145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway.
    Shen J; Zhou Y; Zhang X; Peng W; Peng C; Zhou Q; Li C; Wen T; Shi Y
    Aging (Albany NY); 2019 Nov; 11(21):9280-9294. PubMed ID: 31689237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target.
    Gao Q; Yu GY; Shi JY; Li LH; Zhang WJ; Wang ZC; Yang LX; Duan M; Zhao H; Wang XY; Zhou J; Qiu SJ; Jeong LS; Jia LJ; Fan J
    Oncotarget; 2014 Sep; 5(17):7820-32. PubMed ID: 25229838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.